Aquestive Therapeutics Inc

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aquestive Therapeutics reports robust 2022 performance and strategic growth plans

Aquestive Therapeutics showcased strong performance in 2022, focusing on innovation, strategic partnerships, and financial management.
While facing challenges such as generic competition and financial discipline, the company is well-positioned to capitalize on opportunities for growth and market expansion.
With a clear emphasis on advancing key products, securing collaborations, and navigating market dynamics, Aquestive is poised for continued success in 2023 and beyond.

Aquestive Therapeutics reports strong Q1 performance and eyes global expansion

Aquestive Therapeutics' Q1 performance reflects strong revenue growth, debt reduction, and strategic advancements in product development.
While facing challenges in European pricing and Chinese market visibility, the company maintains a focus on operational efficiency and market expansion.
Opportunities in FDA interactions, market access, and upcoming regulatory meetings position Aquestive for future growth and product success.
Overall, Aquestive Therapeutics demonstrates resilience and strategic planning in navigating market challenges and driving growth.

Aquestive Therapeutics reports improved Q2 performance and eyes global expansion

Aquestive Therapeutics reported a strong Q2 2023 performance with revenue growth and reduced net loss. The company faces financial challenges but holds strengths in its financial position and growth outlook. Opportunities for expansion and partnerships present avenues for future growth.

Aquestive Therapeutics reports strong Q3 performance and optimistic growth outlook

Aquestive Therapeutics showcased robust financial performance, strategic debt refinancing, and promising product developments in Q3 2023. While facing challenges in competitive intelligence and trial efficiency, the company is optimistic about future growth opportunities and remains focused on expanding its capabilities.

Aquestive reports robust Q4 earnings, eyes billion-dollar sales opportunities

Aquestive Therapeutics showcases strong financial performance in Q4 2023, with revenue growth and improved EBITDA loss, setting a positive trajectory for future growth. Strategic focus on launching Anaphylm and Libervant, along with proactive commercial preparations, underlines the company's commitment to innovation and market expansion. Despite regulatory and competitive challenges, Aquestive's confidence in FDA processes and international market exploration present promising opportunities for long-term success.

Aquestive Therapeutics reports revenue growth and plans for future launches

Aquestive Therapeutics reported revenue growth in Q3 2024 driven by successful product launches and positive study results, despite increased expenses.
The company's focus on key programs and upcoming milestones signals a commitment to innovation and addressing market needs for sustained growth.
While facing challenges in managing expenses and profitability, Aquestive's strong financial position and strategic initiatives offer opportunities for future growth and market expansion.
Overall, Aquestive's performance in Q3 2024 reflects a balance between investment in future growth and financial stability, positioning the company for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WARREN, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the refinancing of its existing debt facility.

Aquestive Therapeutics Completes $45 Million Debt Refinancing

The latest trading day saw Aquestive Therapeutics (AQST) settling at $1.54, representing a -1.91% change from its previous close.

Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to Know

In the closing of the recent trading day, Aquestive Therapeutics (AQST) stood at $1.43, denoting a +1.42% change from the preceding trading day.

Aquestive Therapeutics (AQST) Beats Stock Market Upswing: What Investors Need to Know

WARREN, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided a business update on its lead pipeline programs and base business results.

Aquestive Therapeutics Provides Business Update

ARS Pharmaceuticals Inc

Both ARS Pharmaceuticals and Aquestive Therapeutics are developing non-injectable epinephrine products for anaphylaxis, with potential to capture significant market share from current standard (auto-injectors). At current prices I expect that upside of either stock if successful will significantly outweight downside risk for the other stock, while upside potential from both stocks is not unlikely. Risks include regulatory delays (unlikely for SPRY but possible for AQST), several competing nasal epinephrine devices under clinical development (a major risk to SPRY) and precarious financial situation of AQST.

ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both

Aquestive (AQST) stock rises 11.8% as the company intends to begin a pivotal pharmacokinetic study of Anaphylm as an oral epinephrine product candidate in the fourth quarter of 2023.

Aquestive (AQST) Up on Reaffirming Anaphylm Development Pathway

WARREN, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on the development timeline and pathway for its oral epinephrine product candidate, Anaphylm™.

Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film

Aquestive Therapeutics (AQST) closed at $1.66 in the latest trading session, marking no change from the prior day.

Aquestive Therapeutics (AQST) Flat As Market Gains: What You Should Know

Aquestive (AQST) announces FDA acceptance of a regulatory application seeking approval for Libervant to treat pediatric patients with frequent seizure activity. The stock rises 4.7% in response.

Aquestive's (AQST) Libervant Accepted for FDA Review, Stock Up

Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Bennett Watson - Investor Relations, ICR Westwicke Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice President, Chief Financial Officer Steve Wargacki - Senior Vice President, Research and Development Ken Marshall - Senior Vice President, Chief Commercial Officer Carl Kraus - Chief Medical Officer Conference Call Participants Jason Butler - JMP François Brisebois - Oppenheimer Thomas Flaten - Lake Street Capital Markets Raghuram Selvaraju - H.C. Wainwright Operator Good morning and welcome to the Aquestive Therapeutics Second Quarter 2023 Conference Call.

Aquestive Therapeutics, Inc. (AQST) Q2 2023 Earnings Call Transcript

WARREN, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today reported financial results for the second quarter ended June 30, 2023 and provided an update on recent developments in its business.

Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

WARREN, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the management team will participate in the 2023 Wedbush PacGrow Healthcare Conference in New York. The Aquestive team will host investor meetings at the conference on August 9th.

Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference

Aquestive's (AQST) second-quarter 2023 revenues are likely to have been driven by rising licensed product revenues.

Aquestive (AQST) to Report Q2 Earnings: What's in Store?

Anaphylm, epinephrine sublingual film is a better solution to existing and in-development epinephrine formulations to treat anaphylaxis, a $1 billion/year market. Pharmacokinetic studies have shown faster onset of action and comparable serum levels of epinephrine as existing injectable formulations. The company is finalizing the pivotal study protocol and NDA submission is expected next year, with potential approval.

Aquestive Therapeutics: Developing A Better Solution To A $1 Billion/Year Anaphylaxis Problem

WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today announced that it will report results for the second quarter ended June 30, 2023, and provide an update on recent developments in its business after market close on Monday, August 7, 2023.

Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET

WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today announced that two posters recapping the positive topline data from pharmacokinetic (PK) and pharmacodynamic (PD) studies of Anaphylm epinephrine sublingual film will be presented at the Aspen Allergy Conference, which will be held from July 30 – August 3 in Aspen, CO.

Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference

Aquestive Therapeutics (AQST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down -31.17% in 4 Weeks, Here's Why Aquestive Therapeutics (AQST) Looks Ripe for a Turnaround

WARREN, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on recent business developments and announced the appointment of Carl N. Kraus, M.D. as Chief Medical Officer of the Company.

Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment

WARREN, N.J., May 31, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today released topline clinical data from recent pilot studies that were completed following the End-of-Phase 2 meeting with the FDA. The studies included examining (1) differences in pharmacokinetic (PK) results based on changes to administration instructions, (2) additional repeat dose data on Anaphylm, and (3) the differences between approved auto-injectors.

Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study

Does Aquestive Therapeutics (AQST) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Aquestive Therapeutics (AQST) is a Great Choice

Playtika Holding

Woodward

AQST, PLTK and WWD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 9, 2023.

Best Momentum Stocks to Buy for May 9th

Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q1 2023 Earnings Conference Call May 3, 2023 8:00 AM ET Company Participants Bennett Watson - Investor Relations, ICR Westwicke Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice President, Chief Financial Officer Steve Wargacki - Senior Vice President, Research and Development Ken Marshall - Senior Vice President, Chief Commercial Officer Conference Call Participants Jason Butler - JMP Securities Francois Brisebois - Oppenheimer Thomas Flaten - Lake Street Capital Markets Caroline Pocher - Wedbush Securities Raghuram Selvaraju - H.C. Wainwright & Company Operator Good morning and welcome to the Aquestive Therapeutics First Quarter 2023 Conference Call.

Aquestive Therapeutics, Inc. (AQST) Q1 2023 Earnings Call Transcript

Aquestive Therapeutics (AQST) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.32 per share a year ago.

Aquestive Therapeutics (AQST) Tops Q1 Earnings and Revenue Estimates

WARREN, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today reported financial results for the first quarter ended March 31, 2023 and provided an update on recent developments in its business.

Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Aquestive Therapeutics Inc Stock (AQST)